Published in Aliment Pharmacol Ther on May 01, 2001
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am (2010) 1.58
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer (2013) 0.91
Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One (2013) 0.89
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm (2016) 0.83
Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut Liver (2016) 0.82
Long-term effects of antiviral therapy in patients with chronic hepatitis C. Hepat Res Treat (2010) 0.81
Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol (2014) 0.80
Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol (2007) 0.79
Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol (2017) 0.77
Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol (2013) 0.76
Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. Int J Mol Sci (2016) 0.75
Hepatitis C: new therapeutic strategies needed for advanced disease. Nat Rev Gastroenterol Hepatol (2009) 0.75
Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol (2014) 0.75
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol (2016) 0.75
Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol (2015) 0.75
Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med (1981) 3.17
Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology (1983) 2.36
Detection of hepatitis B virus DNA directly in human serum by a simplified molecular hybridization test: comparison to HBeAg/anti-HBe status in HBsAg carriers. Hepatology (1983) 2.10
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol (2001) 1.39
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 1.38
Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat (2008) 1.22
Hepatitis-associated antigen in chronic liver disease. Lancet (1970) 1.19
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat (2001) 1.10
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut (2003) 1.08
Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat (2005) 1.06
Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. Hepatology (1985) 1.05
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology (1995) 1.05
Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology (1988) 1.02
Alpha-chain disease with clinical, immunological, and histological recovery. Br Med J (1974) 1.02
Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat (1998) 1.02
Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol (1997) 1.00
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology (1997) 0.96
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat (2008) 0.95
Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther (2004) 0.94
Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol (1999) 0.91
Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat (2009) 0.91
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat (2013) 0.90
Gliclazide-induced acute hepatitis. Eur J Gastroenterol Hepatol (2000) 0.89
Hepatocellular carcinoma and type B hepatitis. Clin Gastroenterol (1980) 0.86
Immune thrombocytopenia and alpha-interferon therapy. J Hepatol (1996) 0.86
Hepatitis G virus infection: clinical characteristics and response to interferon. J Viral Hepat (1997) 0.85
Prolonged cholestatic jaundice after endoscopic retrograde cholangiography. Hepatogastroenterology (1997) 0.85
Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B. J Viral Hepat (2008) 0.83
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther (2006) 0.83
Chronic hepatitis B. Prog Liver Dis (1990) 0.83
Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat (1997) 0.82
Chronic viral hepatitis. Clin Gastroenterol (1974) 0.82
Nonparenteral transmission of viral hepatitis in Greece. Am J Med Sci (1977) 0.82
Recurrent hepatic sarcoidosis following liver transplantation. Transplant Proc (1997) 0.81
Absence of the negative strand of GBV-C/HGV RNA from the liver. J Hepatol (1999) 0.81
Does delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma? Br Med J (Clin Res Ed) (1984) 0.80
High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. J Gen Virol (2011) 0.79
Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol (1997) 0.79
Splenic infarct as a late complication of liver transplantation. Eur J Gastroenterol Hepatol (1998) 0.78
Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity. J Viral Hepat (1996) 0.77
Measurement of hepatitis B viral DNA in serum by solution hybridization and comparison with the dot-blot hybridization technique. Hepatogastroenterology (1991) 0.77
Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther (2001) 0.77
Emergence of the long form of hepatitis delta virus antigen in transfected cells after intrahepatic transfection and during natural infection. Prog Clin Biol Res (1993) 0.77
Endemic hepatitis delta virus infection in a Greek community. Prog Clin Biol Res (1987) 0.77
Molecular pathophysiology of persistent hepatitis B virus infection in relation to chronic liver disease and primary hepatocellular carcinoma. Monogr Pathol (1987) 0.76
Letter: Hepatitis-B core antigen and antibody in primary liver cancer. Lancet (1975) 0.76
Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. J Hepatol (1998) 0.76
Sweat gland carcinoma in a patient with sarcoidosis and primary biliary cirrhosis. Dermatology (1994) 0.75
Autoimmune hepatitis associated with the antiphospholipid syndrome. Eur J Gastroenterol Hepatol (2001) 0.75
Decreasing prevalence of hepatitis D virus infection. J Gastroenterol Hepatol (1997) 0.75
Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C. Aliment Pharmacol Ther (2011) 0.75
Letter: Detection of HBAg by passive haemagglutination. Lancet (1974) 0.75
Delta antigen positive chronic liver disease in Greece: clinical aspects and natural course. Prog Clin Biol Res (1983) 0.75
Research as a part of education. Scand J Gastroenterol Suppl (1989) 0.75
Australia antigen in a family. Lancet (1970) 0.75
Deep jaundice in an adolescent. Postgrad Med J (2003) 0.75
Hepatitis B vaccine in haemodialysis patients. Lancet (1984) 0.75
Modern trends in the management of hepatocellular carcinoma. Drugs Exp Clin Res (1986) 0.75
Use of a monoclonal antibody in the detection of HBsAg in the liver by immunofluorescence. Dev Biol Stand (1983) 0.75
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. J Hepatol (1990) 0.75
Primary liver cancer and its relationship to chronic infection with the hepatitis B virus. Springer Semin Immunopathol (1981) 0.75
Proliferative activity in colonic adenomas as a predictor of metachronous adenomas as assessed by proliferating cell nuclear antigen immunohistochemistry. Am J Gastroenterol (1995) 0.75
The precore sequence of hepatitis B virus is required for nuclear localization of the core protein. Hepatology (1997) 0.75
HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Bone Marrow Transplant (1998) 0.75
Size of the speciality. Scand J Gastroenterol Suppl (1989) 0.75
Serum HBV-DNA in delta antigen positive chronic liver disease. Dev Biol Stand (1985) 0.75
Acute rhabdomyolysis following quail consumption. Ann Saudi Med (2007) 0.75
Fulminant hepatitis after flutamide treatment. J Hepatol (1994) 0.75